Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...

Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...

Progress has been made in identifying and treating the disease, but the impact of federal cuts is yet to be borne out.

Zydus Lifesciences' consolidated revenue from operations grew 17% year-on-year to ₹6,123.2 crore, while net profit grew 38% ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Lee May, diagnosed with aggressive multiple myeloma at 59, defied odds with cutting-edge treatments at UCSF Health, including ...

(Reuters) -Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded ...

Teva Pharmaceutical Industries is able to absorb any potential tariffs imposed by the Trump administration, the company said ...

The company’s total revenue from operations in Q2FY26 increased nearly 9% to ₹14,478.31 crore from ₹13,291.39 crore, ...

Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...